Does the media prefer RXRX or RZLT?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 1 mentions for Rezolute. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Rezolute's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RZLT or NTLA?

In the previous week, Intellia Therapeutics had 10 more articles in the media than Rezolute. MarketBeat recorded 11 mentions for Intellia Therapeutics and 1 mentions for Rezolute. Intellia Therapeutics' average media sentiment score of 0.49 beat Rezolute's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, DMRA or RZLT?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$3.37 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is DMRA or RZLT more profitable?

Rezolute's return on equity of -58.82% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -176.39% -77.86% Rezolute N/A -58.82% -54.48%

Does the media favor DMRA or RZLT?

In the previous week, Damora Therapeutics, Inc. Common Stock had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Rezolute. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.76 beat Rezolute's score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RZLT or SNDX?

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 1 mentions for Rezolute. Syndax Pharmaceuticals' average media sentiment score of 0.98 beat Rezolute's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ANAB or RZLT?

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 7.17 -$13.23M -$1.08 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is ANAB or RZLT more profitable?

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% Rezolute N/A -58.82% -54.48%

Does the media favor ANAB or RZLT?

In the previous week, AnaptysBio had 2 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Rezolute. AnaptysBio's average media sentiment score of 1.15 beat Rezolute's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rezolute (RZLT) Competitors

$4.58 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

RZLT vs. RXRX, NTLA, DMRA, SNDX, and ANAB

Should you buy Rezolute stock or one of its competitors? Rezolute's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), Intellia Therapeutics (NTLA), Damora Therapeutics, Inc. Common Stock (DMRA), Syndax Pharmaceuticals (SNDX), and AnaptysBio (ANAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rezolute compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Rezolute has lower revenue, but higher earnings than Recursion Pharmaceuticals. Rezolute is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	26.02	-$644.76M	-$1.04	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Recursion Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 1 mentions for Rezolute. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Rezolute's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Recursion Pharmaceuticals presently has a consensus target price of $8.06, indicating a potential upside of 122.04%. Rezolute has a consensus target price of $9.38, indicating a potential upside of 104.69%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts clearly believe Recursion Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Rezolute has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Rezolute	N/A	-58.82%	-54.48%

Summary

Recursion Pharmaceuticals beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Intellia Therapeutics?

Rezolute (NASDAQ:RZLT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Rezolute has higher earnings, but lower revenue than Intellia Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Intellia Therapeutics	$67.67M	26.38	-$412.69M	-$3.36	N/A

Rezolute has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 104.69%. Intellia Therapeutics has a consensus target price of $21.15, indicating a potential upside of 66.03%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Intellia Therapeutics had 10 more articles in the media than Rezolute. MarketBeat recorded 11 mentions for Intellia Therapeutics and 1 mentions for Rezolute. Intellia Therapeutics' average media sentiment score of 0.49 beat Rezolute's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rezolute has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

Summary

Intellia Therapeutics beats Rezolute on 10 of the 16 factors compared between the two stocks.

How does Rezolute compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

In the previous week, Damora Therapeutics, Inc. Common Stock had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Rezolute. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.76 beat Rezolute's score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $44.00, indicating a potential upside of 46.37%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 104.69%. Given Rezolute's higher possible upside, analysts clearly believe Rezolute is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rezolute's return on equity of -58.82% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Rezolute	N/A	-58.82%	-54.48%

Summary

Rezolute beats Damora Therapeutics, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

How does Rezolute compare to Syndax Pharmaceuticals?

Rezolute (NASDAQ:RZLT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Syndax Pharmaceuticals and 1 mentions for Rezolute. Syndax Pharmaceuticals' average media sentiment score of 0.98 beat Rezolute's score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Rezolute has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Rezolute's return on equity of -58.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Rezolute has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Syndax Pharmaceuticals	$172.35M	10.57	-$285.42M	-$2.51	N/A

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 104.69%. Syndax Pharmaceuticals has a consensus target price of $42.30, indicating a potential upside of 105.74%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Rezolute beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Rezolute compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

83.0% of Rezolute shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AnaptysBio presently has a consensus target price of $79.85, indicating a potential upside of 40.57%. Rezolute has a consensus target price of $9.38, indicating a potential upside of 104.69%. Given Rezolute's higher probable upside, analysts plainly believe Rezolute is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Rezolute	N/A	-58.82%	-54.48%

AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, AnaptysBio had 2 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Rezolute. AnaptysBio's average media sentiment score of 1.15 beat Rezolute's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	7.17	-$13.23M	-$1.08	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Summary

AnaptysBio beats Rezolute on 10 of the 15 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$441.01M	$3.99B	$7.21B	$12.89B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-5.59	12.71	273.84	25.45
Price / Sales	N/A	1,344.29	625.56	100.83
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	2.46	16.40	11.01	6.39
Net Income	-$74.41M	-$22.85M	$3.49B	$358.69M
7 Day Performance	-2.35%	1.43%	1.63%	0.22%
1 Month Performance	-2.35%	6.00%	4.42%	-0.10%
1 Year Performance	-42.75%	49.38%	24.21%	14.04%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.0343 of 5 stars	$4.58 flat	$9.38 +104.7%	-42.8%	$441.01M	N/A	N/A	40
RXRX Recursion Pharmaceuticals	1.6584 of 5 stars	$3.34 -1.9%	$8.06 +141.7%	-21.3%	$1.79B	$74.68M	N/A	400	Gap Down
NTLA Intellia Therapeutics	2.7474 of 5 stars	$12.59 -1.1%	$21.15 +68.0%	+5.6%	$1.75B	$67.67M	N/A	600
DMRA Damora Therapeutics, Inc. Common Stock	2.618 of 5 stars	$28.18 flat	$44.00 +56.1%	+910.4%	$1.74B	N/A	N/A	40	Gap Down
SNDX Syndax Pharmaceuticals	2.8475 of 5 stars	$19.51 +1.1%	$41.55 +112.9%	+20.7%	$1.73B	$172.35M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. RXRX, NTLA, DMRA, SNDX, and ANAB

How does Rezolute compare to Recursion Pharmaceuticals?

Summary

How does Rezolute compare to Intellia Therapeutics?

Summary

How does Rezolute compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Rezolute compare to Syndax Pharmaceuticals?

Summary

How does Rezolute compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. RXRX, NTLA, DMRA, SNDX, and ANAB

How does Rezolute compare to Recursion Pharmaceuticals?

Which has better earnings and valuation, RXRX or RZLT?

Which has more risk & volatility, RXRX or RZLT?

Does the media prefer RXRX or RZLT?

Do institutionals and insiders believe in RXRX or RZLT?

Do analysts prefer RXRX or RZLT?

Is RXRX or RZLT more profitable?

Summary

How does Rezolute compare to Intellia Therapeutics?

Which has better valuation and earnings, RZLT or NTLA?

Is RZLT or NTLA more profitable?

Do insiders & institutionals believe in RZLT or NTLA?

Do analysts rate RZLT or NTLA?

Does the media prefer RZLT or NTLA?

Which has more risk and volatility, RZLT or NTLA?

Summary

How does Rezolute compare to Damora Therapeutics, Inc. Common Stock?

Which has stronger earnings & valuation, DMRA or RZLT?

Does the media favor DMRA or RZLT?

Do analysts prefer DMRA or RZLT?

Which has more volatility and risk, DMRA or RZLT?

Do institutionals & insiders have more ownership in DMRA or RZLT?

Is DMRA or RZLT more profitable?

Summary

How does Rezolute compare to Syndax Pharmaceuticals?

Does the media prefer RZLT or SNDX?

Which has more risk & volatility, RZLT or SNDX?

Is RZLT or SNDX more profitable?

Which has preferable earnings & valuation, RZLT or SNDX?

Do institutionals & insiders have more ownership in RZLT or SNDX?

Do analysts recommend RZLT or SNDX?

Summary

How does Rezolute compare to AnaptysBio?

Do institutionals and insiders believe in ANAB or RZLT?

Do analysts rate ANAB or RZLT?

Is ANAB or RZLT more profitable?

Which has more risk & volatility, ANAB or RZLT?

Does the media favor ANAB or RZLT?

Which has higher earnings and valuation, ANAB or RZLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools